TARA — Protara Therapeutics Share News
0.000.00%
Last trade - 00:00Protara Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Protara Therapeutics Q3 EPS USD -0.87
Protara Therapeutics Inc expected to post a loss of 98 cents a share - Earnings Preview
Brief: Protara Therapeutics Announces Dosing Of First Patient In Phase 2 Starborn-1 Trial Of Tara-002 In Pediatric Patients
Protara Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Protara Therapeutics Announces Second Quarter 2023 Financial Results And Business Update
Brief: Protara Therapeutics posts Q2 EPS USD -1
Brief: Protara Therapeutics Announces Dosing Of First Patients In Phase 1B Advanced-1EXP Trial Of TARA-002
Protara Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Protara Therapeutics Inc Continues To ExpecT Investments Of $90 Million To Fund Operations Into 2025
U.S. STOCKS ON THE MOVE-Icahn Enterprises, T Rowe Price, Dell Technologies
U.S. STOCKS ON THE MOVE-Sysco, Gartner, Molson Coors Beverage
Protara Therapeutics rises as FDA allows mid-stage trial of cell therapy
Brief: Protara Gets FDA Clearance To Start Mid-stage Trial Of Tara-002 In Pediatric Patients With Lymphatic Malformations
Protara Therapeutics Inc expected to post a loss of 88 cents a share - Earnings Preview
Brief: Protara Therapeutics Announces Positive Preliminary Data From Advanced-1 Phase 1A Dose Escalation Trial Of Tara-002 In Nmibc Supporting Advancement Into Phase 2 Clinical Development
Brief: Protara Therapeutics Inc - Maintain An Operating Account With Svb, Which Holds Funds Typically Use To Pay Monthly Operating Expenses
Protara Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Protara Therapeutics Reports Fourth Quarter